ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
If you want more trading ideas like this one ,ðŊ press a thumb up! ð Have a question? Don't be shy to ask! ðĪ Interested to study how to analyze charts, follow me!
If you want more trading ideas like this one ,ðŊ press a thumb up! ð Have a question? Don't be shy to ask! ðĪ Interested to study how to analyze charts, follow me!